Skip to main content
. 2021 Dec 22;11(1):17. doi: 10.3390/cells11010017

Figure 4.

Figure 4

Correlation between the percent decrease in VEGFR-1+CD14/CD45+ cells and clinical outcome. The percentage of VEGFR-1+CD14/CD45+ cells was determined by cytometry before (T1) and at the end of anti-angiogenic therapy (T3). Patients were classified into two groups according to a cutoff value of 20% decrease in VEGFR-1+CD14/CD45+ cells. Results for (A) progression-free survival (PFS) and (B) overall survival (OS) are presented. For PFS, the group with >20% decrease included 40 patients and the group with <20% decrease included 12 patients. For OS, the group with >20% decrease included 45 patients and the group with <20% decrease included 13 patients. Log-rank test was used for the statistical analysis.